Adult ADHD: the condition that walks into the office under another name

A 38-year-old journalist seeks care for job burnout. She has already tried cognitive-behavioral therapy for fear of failure and emotional instability, without result. She procrastinates, misses deadlines, cannot finish what she starts. At home she cannot keep a routine or manage details — her marriage and her relationship with her children suffer. She sleeps poorly. She has obesity.

That is the case that opens the clinical review on adult ADHD published in the New England Journal of Medicine in October 2026. The authors' conclusion is direct: this patient has ADHD, was never diagnosed, and the burnout and anxiety are the consequence — not the cause.

She is not the exception. She is the pattern.

What adult ADHD is not

For decades, ADHD was treated as a childhood condition: the restless boy who disrupts the class. The implicit idea was that it "went away" with age.

Follow-up studies dismantled that. In at least one third of cases, symptoms persist into adulthood, and functional impairment persists in an even larger proportion. The estimated prevalence in young adults is about 2.5% — roughly 1 in 40 people — with similar rates in men and women.

What changes is the presentation. The child's motor hyperactivity becomes inner restlessness in the adult: difficulty relaxing, sitting still, enjoying a moment of leisure without being "switched on". Inattention shows up as an inability to plan, organize and manage time. Impulsivity translates into interrupting others, answering before thinking, making hasty decisions — uncontrolled spending is a classic example.

There is also a component that is not part of the formal criteria but is present in most adults with ADHD: emotional dysregulation — short-lived, disproportionate reactions, irritability, verbal outbursts. It is frequently the reason for the visit, and frequently leads to the wrong diagnosis.

Why the diagnosis is missed

The adult with undiagnosed ADHD enters the health system through one of four doors: because of the attention symptoms themselves (the minority); because of an associated psychiatric condition; because of an associated physical illness; or — increasingly — through self-diagnosis via the internet and social media.

Through the two middle doors, ADHD usually stays invisible. Most adults with ADHD have at least one other psychiatric condition: anxiety, depression, sleep disorders, substance use, personality disorders. The doctor treats the anxiety. The anxiety improves little, because the underlying mechanism — the inability to organize one's own life — remains intact.

One finding deserves specific attention: in people with treatment-resistant depression, unrecognized ADHD is one of the factors that explain treatment failure. Antidepressant after antidepressant, without response, should prompt the question.

Women are diagnosed later

Girls with ADHD are generally less disruptive than boys. They learn to compensate and to mask. They reach adulthood undiagnosed and seek help for anxiety and depression — and that is what they receive as a diagnosis. Hormonal fluctuations (menstrual cycle, pregnancy, postpartum, menopause) modulate attention and impulsivity and can both mimic and worsen ADHD.

People with high cognitive ability

Those with high intellectual potential compensate for longer. The impairment does not show up as "failure", but as performance below what the person could clearly deliver — and nobody investigates because, after all, "she is doing fine". The NEJM review is explicit: in these cases, the relevant criterion is performance relative to potential, not absolute performance.

The cost of not diagnosing

Here the conversation stops being about productivity and becomes about health.

ADHD is a condition with a strong biological basis — heritability around 80%, with measurable differences in brain circuits modulated by dopamine and norepinephrine. And it is associated with a long list of physical conditions: obesity, cardiovascular and cerebrovascular disease, type 1 and type 2 diabetes, inflammatory and immune conditions. Part of this association is shared genetics; part is behavioral — diet, sedentary lifestyle, smoking, substance use, delay in seeking care and poor adherence to treatment.

The aggregate outcome is serious: the life expectancy of adults with diagnosed ADHD is about 7 years shorter in men and 9 years shorter in women than that of matched controls, according to a 2025 British cohort study with more than 30,000 primary care patients. The authors attribute the difference to modifiable factors and unmet treatment needs — both for ADHD and for the associated conditions.

If you have read this site's article on obesity as an inflammatory disease, it is worth connecting the dots: the patient with obesity who "cannot stick to the plan" may have a neurobiological mechanism working against them — and in that case, treating the ADHD is part of treating the obesity.

How the diagnosis is made

ADHD is a clinical diagnosis. There is no blood test, imaging study or neuropsychological test that confirms or rules it out. Tests can help characterize it, but they do not replace the interview.

The process that international guidelines (NICE, Canadian, Australian) converge in recommending is:

• Structured clinical interview about current symptoms and their history since childhood.
• Standardized rating scales to collect symptoms and domains of impairment systematically — useful, but never sufficient on their own. ADHD is not diagnosed by questionnaire.
• Collateral informant — partner, father, mother — about current and past symptoms. Retrospective memory of one's own childhood is unreliable, especially in those who had a supportive family and school environment, low cognitive demands or high intelligence.
• Assessment of comorbidities, psychiatric and physical, and of context: work, marital relationship, parenting, self-esteem.

Two points of caution the review emphasizes. First: attention symptoms that occur exclusively during heavy substance use or during another psychiatric condition do not justify the diagnosis. Second: generalized anxiety and depression also produce inattention and restlessness — but anxiety does so in the face of anxiety-provoking stimuli, and depression is usually episodic. ADHD is persistent and independent of context.

Treatment — and what applies in Brazil

Treatment has three components: psychoeducation, medication and psychosocial intervention. Medication is what most reduces the core symptoms; psychoeducation is indispensable for the patient to understand that they have a neurobiological condition, not a character flaw.

Medication

Psychostimulants — methylphenidate and the amphetamine derivatives — are the first choice in virtually every guideline. The largest network meta-analysis on the subject, published in 2025, found a moderate and equivalent effect size for the two classes. Long-acting formulations (8 to 12 hours) are the ones recommended for adults, who need coverage during the working day and after it.

In Brazil, the marketed options are methylphenidate (immediate and extended release), lisdexamfetamine and, among the nonstimulants, atomoxetine. The first two are controlled under Ordinance 344/98, with a specific prescription. Mixed amphetamine salts, extended-release guanfacine, viloxazine and centanafadine — cited in the review as alternatives in the US and Europe — are not regularly marketed in the country as of this publication. Bupropion and clonidine are used off-label in selected scenarios.

Nonstimulants have a somewhat smaller and slower effect than stimulants, but they are a legitimate option when there is a contraindication, intolerable adverse effects, risk of misuse or patient preference.

Dependence: what the data show

The most common objection to medication is fear of dependence. The concern has a basis: stimulants have abuse potential — which is why they are controlled — and use outside the prescription can lead to misuse, addiction and overdose. What the data show is that supervised treatment, at the prescribed dose, does not reproduce that risk. Large Scandinavian registry studies and American insurance databases show that stimulant treatment does not increase — and in several studies reduces — the risk of substance use disorder. A 2025 Swedish study of 148,000 patients found reductions in suicidal behavior, substance misuse, transport accidents and criminality among those treated. Treating ADHD in people who use substances is possible and often preferable.

The real risk lies in misuse — doses above the prescribed one, use for euphoria or performance, diversion to others — concentrated in immediate-release formulations and in young adult students. That is managed with long-acting formulations, regular monitoring and attention to signs of misuse, not by denying treatment.

Adverse effects and cardiovascular safety

The most common adverse effects of stimulants are reduced appetite and weight, initial insomnia and a slight increase in heart rate and blood pressure. Long-term treatment carries an increased risk of hypertension. Hence, before prescribing: personal and family history of cardiovascular disease, physical examination with blood pressure, pulse and weight, and an electrocardiogram if there is a relevant finding. Irritability at the peak or at the end of the effect, and a certain emotional "flattening", are possible effects that need to be monitored and adjusted.

The risk of psychotic symptoms exists, is low and is concentrated in vulnerable people or at high doses.

Psychotherapy

Cognitive-behavioral therapy adapted to ADHD — cognitive restructuring, organizational skills training, metacognitive therapy — has a moderate effect on overall and occupational functioning and a limited effect on core symptoms. It does not replace medication, but it treats what medication does not reach: organizational and time-management habits built over decades of compensation. The combination is frequently necessary.

Neurofeedback, devices and therapeutic games have no consistent evidence of efficacy on core symptoms.

What changes in primary care

The review's central message for those on the front line is that the adult with ADHD is being seen by us all the time — for other reasons. Facing that reality means:

• Thinking of the diagnosis in the face of resistant depression, anxiety that does not respond, recurrent burnout, refractory obesity, chronic insomnia, substance use, a history of accidents or traffic fines, professional or financial instability.
• Investigating, not just screening — a scale as the starting point, interview and informant as the basis of the diagnosis.
• Prioritizing ADHD treatment when it precedes and sustains the anxiety or depression. In the NEJM case, the authors treat the ADHD first and reassess the anxiety afterwards.
• Setting concrete targets — two or three individualized symptoms that need to change — and following up with scales every 2 to 4 weeks until stable. A clinically meaningful response requires a 40 to 50% reduction in symptoms.
• Testing doses — the optimal dose is not always obvious; undertreatment out of excessive caution is a common mistake.
• Screening cardiovascular risk before and during treatment.
• Longitudinal follow-up — ADHD is chronic, and the associated physical conditions need active surveillance throughout life.

For the patient

If you recognized yourself in the case that opens this article — or recognized someone —, the question is not "am I disorganized?". Everyone is, sometimes. The question is: is this costing me something real, in more than one area of life, for a long time? Work, relationships, money, driving, health.

If the answer is yes, that deserves structured investigation — not an internet test, and not the conclusion that the problem is a lack of discipline. Adult ADHD is a medical condition with a well-described biological basis, effective treatment and serious consequences when ignored. A diagnosis at 30, 40 or 50 is not late. It is the beginning of an explanation for a great deal.